Drug Name: Veopoz
Indications: To treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.
Active Ingredient: Pozelimab-bbfg
Company: Regeneron Pharmaceuticals, Inc.
Approval Date: 8/18/2023
More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761339s000lbl.pdf